Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.43 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23360259 | 0.99 | ALK (0.50) | ALKKCNH2ROCK1NCF1MET | |
| Hydrochloric Acid SCHEMBL29862461 | 0.99 | ALK (0.50) | ALKKCNH2ROCK1NCF1MET | |
| Hydrochloric Acid SCHEMBL23360167 | 0.89 | NCF1 (0.54) | ALKKCNH2ROCK1NCF1HTR1A | |
| SCHEMBL24837609 | 0.84 | HTR1A (0.44) | ALKKCNH2METHTR1AADRA1D | |
| SCHEMBL24010701 | 0.84 | HTR1A (0.44) | ALKKCNH2METHTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL23359655 | 0.83 | KRAS (0.55) | NCF1KRASSOS1TGFBR1 | |
| Hydrochloric Acid SCHEMBL29862588 | 0.83 | ALK (0.47) | ALKKCNH2ROCK1HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL23360666 | 0.83 | ALK (0.47) | ALKKCNH2ROCK1HTR1AADRA1D | |
| SCHEMBL29862704 | 0.82 | NCF1 (0.50) | KCNH2ROCK1NCF1HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL23360370 | 0.81 | NCF1 (0.49) | KCNH2ROCK1NCF1HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | ALK 2143/4885KCNH2 4285/4885ROCK1 905/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | ALK 2143/4885KCNH2 4285/4885ROCK1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.